Isomorphic Labs announces it has raised $600 Million in its first external funding round. The financing round is led by Thrive Capital, with participation from GV, and follow-on capital from existing investor, Alphabet. Isomorphic Labs was founded with the ambition to leverage the power of AI to reimagine and accelerate drug discovery to bring much-needed treatments to millions of patients globally. The company aims to apply its pioneering AI drug design engine to deliver biomedical breakthroughs and is advancing drug design programs across multiple therapeutic areas and drug modalities.
Read more in the news release below.
0
a--up
No items found.
a--up
2
2
1
.png)
No items found.
0
a--up
none
0
a--up
none
No items found.
a--up
2
2
1
No items found.
0
a--up
none
0
a--up
none
.svg)
